title: The clinical role of CT/PET in oncology: an update.
abstract: FDG-PET imaging has significantly altered the workup of the oncologic patient. With the introduction of combined FDG-PET/CT scanners, there has been a dramatic improvement in lesion detection, lesion characterization and accurate lesion localization. As attenuation correction can be attained with the CT images, PET exam times have been dramatically reduced, by as much as 50% in many instances. In this overview we briefly outline the advantages of CT/PET in oncology especially in diagnosis and clinical management of the common tumor types for which it is mainly used.
authors.affiliation: Division of Abdominal Imaging, Department of Radiology, University of Michigan Hospitals, Ann Arbor, MI 48109-0030, USA. ifrancis@umich.edu
authors.forename: Isaac R
authors.initials: IR
authors.lastname: Francis
authors.forename: Richard K J
authors.initials: RK
authors.lastname: Brown
authors.forename: Anca M
authors.initials: AM
authors.lastname: Avram
mesh_terms: D003110:Colonic Neoplasms / Q000175:diagnosis; D019788:Fluorodeoxyglucose F18; D006258:Head and Neck Neoplasms / Q000175:diagnosis; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis; D008223:Lymphoma / Q000175:diagnosis; D008545:Melanoma / Q000175:diagnosis; D009367:Neoplasm Staging; D009369:Neoplasms / Q000175:diagnosis* / Q000628:therapy; D049268:Positron-Emission Tomography; D018787:Radiation Oncology / Q000639:trends*; D019275:Radiopharmaceuticals; D011880:Radiotherapy Planning, Computer-Assisted; D014057:Tomography, X-Ray Computed
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18